- Home
- SQFT vs CANF Comparison
SQFT vs CANF Comparison
Compare SQFT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- CANF
- Stock Information
- Founded
- SQFT 1999
- CANF 1994
- Country
- SQFT United States
- CANF Israel
- Employees
- SQFT N/A
- CANF N/A
- Industry
- SQFT Real Estate Investment Trusts
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- CANF Health Care
- Exchange
- SQFT Nasdaq
- CANF Nasdaq
- Market Cap
- SQFT 8.1M
- CANF 9.4M
- IPO Year
- SQFT 2020
- CANF N/A
- Fundamental
- Price
- SQFT $0.61
- CANF $1.55
- Analyst Decision
- SQFT
- CANF Strong Buy
- Analyst Count
- SQFT 0
- CANF 2
- Target Price
- SQFT N/A
- CANF $14.00
- AVG Volume (30 Days)
- SQFT 23.3K
- CANF 113.1K
- Earning Date
- SQFT 03-18-2025
- CANF 03-21-2025
- Dividend Yield
- SQFT N/A
- CANF N/A
- EPS Growth
- SQFT N/A
- CANF N/A
- EPS
- SQFT N/A
- CANF N/A
- Revenue
- SQFT $18,586,052.00
- CANF $667,000.00
- Revenue This Year
- SQFT N/A
- CANF $409.56
- Revenue Next Year
- SQFT N/A
- CANF N/A
- P/E Ratio
- SQFT N/A
- CANF N/A
- Revenue Growth
- SQFT 5.44
- CANF N/A
- 52 Week Low
- SQFT $0.47
- CANF $1.29
- 52 Week High
- SQFT $1.39
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SQFT 40.86
- CANF 44.03
- Support Level
- SQFT $0.62
- CANF $1.45
- Resistance Level
- SQFT $0.65
- CANF $1.76
- Average True Range (ATR)
- SQFT 0.03
- CANF 0.15
- MACD
- SQFT 0.00
- CANF -0.02
- Stochastic Oscillator
- SQFT 14.29
- CANF 16.95
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).